TAK-279

Phase 3Small molecule

Takeda

TAK-279 is one of 105 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Crohn's DiseaseRecruiting

Ulcerative ColitisActive, not recruiting

Generalized Pustular PsoriasisActive, not recruiting

PsoriasisPhase 3

Active, not recruiting

Crohn's DiseasePhase 2

Recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Generalized Pustular PsoriasisPhase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

TAK-279

Takeda

Phase 3

3 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Generalized Pustular Psoriasis

NCT06323356

Q3 2027

Phase 2Recruiting

Crohn's Disease

NCT06233461

Phase 2Recruiting

Ulcerative Colitis

NCT06254950

Clinical

Trials by Indication[1]

Adult3 trials

A Study of TAK-279 in Healthy Chinese Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06111547·24 enrolled

A Study of TAK-279 in Adults With or Without Liver Damage

Completed· Takeda logo

Takeda·Phase 1·NCT05976321·27 enrolled

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Completed· Takeda logo

Takeda·Phase 1·NCT06258265·120 enrolled

Psoriasis3 trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Completed· Takeda logo

Takeda·Phase 3·NCT06108544·1,108 enrolled

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT06550076·1,950 enrolled

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Completed· Takeda logo

Takeda·Phase 3·NCT06088043·693 enrolled

Interaction2 trials

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT05995249·172 enrolled

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06290050·20 enrolled

Kidney1 trial

A Study of TAK-279 in Adults With or Without Kidney Problems

Completed· Takeda logo

Takeda·Phase 1·NCT05992155·24 enrolled

Generalized Pustular Psoriasis1 trial

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT06323356·18 enrolled

2 more indications

Ulcerative Colitis1 trial

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Takeda logo

Takeda·Phase 2·NCT06254950·207 enrolled

Crohn's Disease1 trial

A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting· Takeda logo

Takeda·Phase 2·NCT06233461·268 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for TAK-279. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-279 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-279. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

TAK-279

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Trials by Indication[1]

Adult3 trials

Psoriasis3 trials

Interaction2 trials

Kidney1 trial

Generalized Pustular Psoriasis1 trial

Ulcerative Colitis1 trial

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News